期刊文献+

新型芳基脲类Raf激酶抑制剂的合成及抗肿瘤活性

Synthesis and Antitumor Activities of Alylurea Derivatives Asnovel Raf Kinase Inhibitors
下载PDF
导出
摘要 目的合成新型芳基脲类Raf激酶抑制剂并评价其抗肿瘤活性。方法以索拉非尼为先导化合物进行结构改造,设计合成系列芳基脲类衍生物,~1H-NMR和ESI-MS鉴定目标物结构,并用MTT法进行体外抗肿瘤活性评价。结果合成11个新目标化合物,其中2个表现出显著的体外抗肿瘤活性。结论抗肿瘤活性好的目标化合物体拟作为候选药做进一步的评价和修饰。 Objective To synthesize novel aryl urea Raf kinase inhibitors and to study their antitumor activity.Methods With SoRafenib as the lead compound,eleven novel aryl urea compounds were designed, synthesized and characterized by ^1H-NMR and ESI-MS. Their antitumor activities were investigated by MTT methods.Results Eleven novel compounds were synthesized,two of which had better antitumor activities.Conclusion Target compourds with good antitumor activities can potentially serve as drug candidates for further evaluation and modification.
出处 《解放军药学学报》 CAS CSCD 2017年第1期21-25,共5页 Pharmaceutical Journal of Chinese People's Liberation Army
基金 国家自然科学基金资助项目 No.30973616
关键词 Raf激酶抑制剂 芳基脲类化合物 抗肿瘤药物 Raf kinase inhibitor alyl urea derivatives compounds antineoplastic agents
  • 相关文献

参考文献4

二级参考文献56

  • 1ARORA A, SCHOLAR EM. Role of tyrosine kinase inhibitors in cancer therapy[ J]. J Pharmacol Exp Ther, 2005, 315 ( 3 ) : 971 - 979.
  • 2BRECCIA M, EFFICACE F, ALIMENA G. Imatinib treatment in chronic myelogenous leukemia: What have we learned so far? [J]. CancerLett, 2011, 300(2):115-121.
  • 3DEININGER MW. Nilotinib [ J]. Clin Cancer Res, 2008, 14 (13) : 4027 -4031.
  • 4SHAYANI S. Dasatinib, a muhikinase inhibitor: therapy, safety, and appropriate management of adverse events [ J ]. Ther Drug Monit, 2010, 32(6):680-687.
  • 5SANTOS FP, KANTARJIAN H, CORTES J, et al. Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia[ J ]. Curr Opin Investig Drugs, 2010, 11 (12) : 1450 - 1465.
  • 6GONTAREWICZ A, BRUMMENDORF TH. Danusertib (formerly PHA-739358 )--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor[J]. Recent Results Cancer Res, 2010, 184:199-214.
  • 7NELSON MH, DOLDER CR. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors[ J]. Ann Pharmacother, 2006, 40(2) :261 -269.
  • 8CAMPBELL L, BLACKHALL F, THATCHER N. Gefitinib for the treatment of non-small-cell lung cancer - J ]. Expert Opin Pharmacother, 2010, 11 (8) : 1343 - 1357.
  • 9GRIDELLI C, MAIONE P, BARESCHINO MA, et al. Erlotinib in the treatment of non-small cell lung cancer: current status and future developments [ J ]. Anticancer Res, 2010, 30 (4) : 1301 - 1310.
  • 10DHILLON S, WAGSTAFF AJ. Lapatinib[ J ]. Drugs, 2007, 67 (14): 2101 -2108.

共引文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部